Characteristics of residual invasive breast cancer after neoadjuvant therapy in the KATHERINE study
- PMID: 34058348
- DOI: 10.1016/j.annonc.2021.05.802
Characteristics of residual invasive breast cancer after neoadjuvant therapy in the KATHERINE study
Conflict of interest statement
Disclosure EPM reports honoraria from Biotheranostics, Daiichi Sankyo, Genentech/Roche, Genomic Health, and Merck; and research funding from the NSABP Foundation.
Comment on
-
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.Ann Oncol. 2021 Aug;32(8):1005-1014. doi: 10.1016/j.annonc.2021.04.011. Epub 2021 Apr 28. Ann Oncol. 2021. PMID: 33932503 Clinical Trial.
-
Association between HER2 status in residual disease and sensitivity to trastuzumab emtansine.Ann Oncol. 2021 Sep;32(9):1191. doi: 10.1016/j.annonc.2021.05.794. Epub 2021 May 21. Ann Oncol. 2021. PMID: 34023398 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical